Now Reading: IICT transfers diabetic wound treatment to Viridis Biopharma
-
01
IICT transfers diabetic wound treatment to Viridis Biopharma
The Indian Institute of Chemical Technology (IICT) has transferred a phytopharmaceutical technology for treating diabetic foot ulcers to Viridis Biopharma Pvt Ltd. The technology, developed from the herb 'Gymnema sylvestre' (Gurmar), is…
The Story in Brief
The Indian Institute of Chemical Technology (IICT) has transferred a phytopharmaceutical technology for treating diabetic foot ulcers to Viridis Biopharma Pvt Ltd. The technology, developed from the herb 'Gymnema sylvestre' (Gurmar), is IND-ready, meaning it has completed preclinical testing. Viridis will now handle regulatory submissions to India's CDSCO and the US FDA, aiming to move the formulation into clinical evaluation.
The research, supported under the CSIR Phytopharmaceutical Mission Phase-III, included botanical standardisation, pharmacological studies, and safety evaluations. IICT director Srinivasa Reddy said the transfer reflects efforts to move research towards healthcare. Viridis director Anslem de Souza stated the treatment fulfils a gap in current wound management. The programme also has potential for other chronic wounds and inflammatory skin disorders.
The Indian Opinion
The claim of a 'sugar destroyer' herb curing diabetic wounds is a narrative that feeds the Indian appetite for miracle botanicals, but the truth is more measured. This is an early-stage transfer, not a cure. The real test will be whether CDSCO and USFDA approval follow the preclinical promise. Indian science needs to resist hype and push for rigorous, transparent clinical trials. The number to watch: how many patients actually heal in Phase II trials.
Source: timesofindia.indiatimes.com
This story was synthesised by AI from the source linked above.
